You are here

Article Text

Article menu
Download PDFPDF
Editorial
Bivalirudin in acute myocardial infarction: NICE guidance

https://doi.org/10.1136/heartjnl-2011-301141

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Footnotes

    • Disclosures Within the past 3 years, GWS served as a consultant for Osprey, Reva, Merck, CoreValve, Boston Scientific, Abbott Vascular, Evalve, AstraZeneca, Prescient, Eli Lilly-Daichii Sankyo partnership, Bristol-Meyers-Squibb-Sanofi partnership, Biosensors, Otsuka, The Medicines Company, Ortho-McNeil, Gilead, InspireMD, Atrium, Volcano, InfraReDx, Medtronic, Genentech, GlaxoSmithKleine, Miracor; received honoraria from Edwards and Vascular Solutions; and has equity in CoreValve, Savacor, Biostar I and II funds, MedFocus I, II and Accelerator funds, Calibre, FlowCardia, Ovalum, MediGuide, Guided Delivery Systems, Arstasis, Micardia, AccessClosure, Embrella and VNT.

    • Funding The HORIZONS-AMI trial.

    • Competing interests None.

    • Patient consent Obtained.

    • Ethics approval Numerous bodies in 17 countries.

    • Provenance and peer review Commissioned; internally peer reviewed.